Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10

Yau JW, Rogers SL, Kawasaki R et al (2012) Meta-Analysis for eye disease (META-EYE) study group. global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564

Article  PubMed  PubMed Central  Google Scholar 

Agarwal D, Gelman R, Prospero Ponce C et al (2015) The vitreomacular interface in diabetic retinopathy. J Ophthalmol 2015:392–983

Article  Google Scholar 

Mehta H, Gabrielle PH, Hashimoto Y et al (2024) One-Year anti-VEGF therapy outcomes in diabetic macular edema based on Treatment intensity: data from the fight retinal blindness! Regist Ophthalmol Retina S2468–6530(24):00182–00189. https://doi.org/10.1016/j.oret.2024.04.008

Article  Google Scholar 

Inaltekin A, Bozkurt E, Kıvrak Y (2021) Factors associated with pain level in patients receiving intravitreal injection. J Curr Ophthalmol 33(3):323–329

Article  PubMed  PubMed Central  Google Scholar 

Levison AL, Kaiser PK (2014) Vitreomacular interface diseases: diagnosis and management. Taiwan J Ophthalmol 4:63–68

Article  Google Scholar 

Xie P, Zheng X, Yu Y et al (2017) Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration. Br J Ophthalmol 101(8):1003–1010

Article  PubMed  Google Scholar 

Akbar KhI, Mohamed MD, Mann SS et al (2015) Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for centre involving diabetic macular oedema. Br J Ophthalmol 99(8):1078–1081

Article  Google Scholar 

Zapata MA, Figueroa MS, Esteban González E et al (2017) SERV-VMT study group. Prevalence of vitreoretinal interface abnormalities on spectral-domain OCT in healthy participants over 45 years of age. Ophthalmol Retina 1(3):249–254

Article  PubMed  Google Scholar 

Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203

Article  PubMed  CAS  Google Scholar 

Lin A, Xia H, Zhang A et al (2022) Vitreomacular interface disorders in proliferative diabetic retinopathy: an optical coherence TOMOGRAPHY STUDY. J Clin Med 11(12):32–66

Article  Google Scholar 

Duman R, Çetinkaya E, Duman R (2018) Vitreomaküler Ara Yüzey Hastalıklarında Klinik. Tanı ve Sınıflandırma Current Retian 2(3):231–235

Google Scholar 

Yayla U, Sevik MO, Karabaş VL et al (2023) Real-world outcomes of intravitreal anti-vascular endothelial growth factor treatment for Diabetic macular edema in Türkiye: MARMASIA study group report No. 1. Turk J Ophthalmol 53:356–368

Article  PubMed  PubMed Central  Google Scholar 

Chang CK, Cheng CK, Peng CH (2017) The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF. Eye (Lond) 31(5):762–770

Article  PubMed  CAS  Google Scholar 

Liew G, Nguyen H, Ho IV et al (2021) Prevalence of vitreoretinal interface disorders in an Australian population: the blue mountains eye study. Ophthalmol Sci 1(2):100019

Article  PubMed  PubMed Central  Google Scholar 

Quinn NB, Steel DH, Chakravarthy U et al (2020) Assessment of the vitreomacular interface using high-resolution OCT in a population-based cohort study of older adults. Ophthalmol Retina 4(8):801–813

Article  PubMed  Google Scholar 

Lin A, Xia H, Zhang A et al (2022) Vitreomacular interface disorders in proliferative diabetic retinopathy: an optical coherence tomography study. J Clin Med 11(12):3266

Article  PubMed  PubMed Central  Google Scholar 

Delyfer MN, Legout P, Le Goff M et al (2020) Prevalence of epiretinal membranes in the ageing population using retinal colour images and SD-OCT: the alienor study. Acta Ophthalmol 98:830–838

Article  Google Scholar 

Jarrar ZA, Ansari AS, Williams KM et al (2023) Prevalence, concordance, and heritability of vitreomacular interface abnormalities in a twin study. Invest Ophthalmol Vis Sci 64(10):9

Article  PubMed  PubMed Central  Google Scholar 

Yoon D, Rusu I, Barbazetto I (2014) Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol 34(4):817–823

Article  PubMed  Google Scholar 

Romano MR, Allegrini D, Guardia CD et al (2019) Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. Graefe’s Arch Clin Exp Ophthalmol 257(1):1–8

Article  CAS  Google Scholar 

Namba R, Kaneko H, Suzumura A et al (2019) In vitro epiretinal membrane model and antibody permeability: relationship with anti-VEGF resistance in diabetic macular edema. Investig Ophthalmol Vis Sci 60(8):2942–2949

Article  CAS  Google Scholar 

Gandorfer A, Messmer EM, Ulbig MW et al (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20(2):126–133

Article  PubMed  CAS  Google Scholar 

Kulikov AN, Sosnovskii SV, Berezin RD et al (2017) Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol 11:1995–2002

Article  PubMed  PubMed Central  Google Scholar 

Mylonas G, Najeeb BH, Goldbach F et al (2022) The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: post hoc analysis of the protocol T study. Retina 42(11):2066–2074

Article  PubMed  CAS  Google Scholar 

Gong Y, Wang M, Li Q et al (2023) Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: a systematic review and meta-analysis. Photodiagnosis Photodyn Ther 42:103555

Article  PubMed  CAS  Google Scholar 

Mikhail M, Stewart S, Seow F et al (2018) Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Graefe’s Arch Clin Exp Ophthalmol 256(8):1411–1418

Article  CAS  Google Scholar 

Comments (0)

No login
gif